Geisinger names Kevin Roberts new CFO

Danville, Pennsylvania’s Geisinger Health System has selected Kevin Roberts, MBA, currently the chief financial officer at St. Louis-based BJC HealthCare, to take over as its new CFO later this year.

Roberts has spent the past decade at BJC following a stint as CFO at University Hospitals Health System in Cleveland. His resume as a financial executive also includes stints at the Cleveland Clinic and Proctor Hospital in Peoria, Illinois, the same city where he earned his MBA from Bradley University.

“It’s an exciting time to be joining Geisinger, an organization with a 100-plus year legacy of providing exceptional care to the communities it serves,” Roberts said in a statement. “I look forward to being part of an innovative and forward-thinking team that keeps patients at the center of everything we do.”

“Throughout his career, Kevin Roberts has demonstrated a commitment to delivering the best in patient care combined with financial expertise,” Geisinger president and CEO David T. Feinberg, MD, MBA, said in a statement.

Roberts will be taking over from Kevin Brennan, who has been with Geisinger for more than 20 years. He’ll continue to work with the system until June, at which time he’ll become the board chair for the Healthcare Financial Management Association (HFMA). Roberts will come on board in April to begin the transition.

“We look forward to the contributions he will make as part of our leadership team and we’re confident he has the exceptional skills necessary to fill the shoes left by Kevin Brennan,” Geisinger president and CEO David Feinberg, MD, MBA, said in a statement.

 

 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.